Sreenivasulu Cherlo, MD
Internal Medicine · Cleveland, TXNPI 1578664116
Payments from drug & device makers
Across 105 payments — averaging $16.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$241
- AstraZeneca$235
- AbbVie$228
- Amgen$139
- Astellas Pharma US Inc$110
- Sunovion Pharmaceuticals Inc.$86
- plus $676 from 20 others
What the payments were for
- Food & beverage$1,70299%
- Education$141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 15 | $241 |
| AstraZeneca | 14 | $235 |
| AbbVie(2 entities) | 12 | $228 |
| Amgen | 8 | $139 |
| Astellas Pharma US Inc | 6 | $110 |
| Sunovion Pharmaceuticals Inc. | 9 | $86 |
| Pfizer | 5 | $85 |
| Sanofi-aventis U.S. LLC | 4 | $66 |
| Johnson & Johnson | 4 | $59 |
| Lilly USA, LLC | 4 | $59 |
| Otsuka America Pharmaceutical, Inc. | 3 | $56 |
| Abbott | 2 | $44 |
| Boehringer Ingelheim | 2 | $34 |
| Novo Nordisk | 2 | $33 |
| Acadia Pharmaceuticals Inc | 2 | $30 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $26 |
| Exact Sciences | 1 | $25 |
| Sumitomo Pharma America, Inc. | 1 | $25 |
| Novartis | 2 | $25 |
| Fidia Pharma USA Inc. | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Mylan Specialty L.p. | 1 | $16 |
| Avanir Pharmaceuticals, Inc. | 1 | $15 |
| CMP Pharma, Inc. | 1 | $14 |
| Radius Health, Inc. | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $13 |
How this compares
$1,716 in reported general payments places this provider in the 75th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 178 | $176,315 |
| MounjaroTirzepatide | 91 | $99,044 |
| EliquisApixaban | 215 | $82,331 |
| FarxigaDapagliflozin Propanediol | 121 | $59,037 |
| IngrezzaValbenazine Tosylate | 14 | $49,866 |
| GemtesaVibegron | 143 | $34,280 |
| JardianceEmpagliflozin | 98 | $32,011 |
| JanuviaSitagliptin Phosphate | 89 | $27,498 |
| XareltoRivaroxaban | 46 | $27,057 |
| XifaxanRifaximin | 19 | $24,187 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $21,884 |
| Sevelamer Carbonate | 17 | $20,505 |
| TrulicityDulaglutide | 13 | $19,251 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 79 | $14,299 |
| RybelsusSemaglutide | 17 | $14,126 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $33 | $190,442195 claims |
| Lilly USA, LLCMounjaro, Trulicity | $59 | $118,295104 claims |
| PfizerEliquis, Abrysvo | $85 | $87,610232 claims |
| AstraZenecaFarxiga, Brilinta, Symbicort | $235 | $69,351146 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat, Glyxambi | $34 | $52,630136 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $25 | $34,280143 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $241 | $27,87444 claims |
| Johnson & JohnsonXarelto | $59 | $27,05746 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $26 | $24,18719 claims |
| AbbVieLinzess | $228 | $12,65416 claims |
| NovartisEntresto | $25 | $12,60330 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Cleveland
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Muhammad IrfanTomball$30.6M
- Aung NaingHouston$30.6M
- Robert BassSan Antonio$25.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Hernan SalazarSan Antonio$18.5M
- Nicholas ShortHouston$17.6M
- Salma SaigerMesquite$16.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.